A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

MLA

Francis, James N., et al. “A Novel Peptide-Based Pan-Influenza A Vaccine: A Double Blind, Randomised Clinical Trial of Immunogenicity and Safety.” Vaccine, vol. 33, no. 2, Jan. 2015, pp. 396–402. EBSCOhost, https://doi.org/10.1016/j.vaccine.2014.06.006.

APA

Francis, J. N., Bunce, C. J., Horlock, C., Watson, J. M., Warrington, S. J., Georges, B., & Brown, C. B. (2015). A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine, 33(2), 396–402. https://doi.org/10.1016/j.vaccine.2014.06.006

Chicago

Francis, James N, Campbell J Bunce, Claire Horlock, Jeannette M Watson, Steven J Warrington, Bertrand Georges, and Carlton B Brown. 2015. “A Novel Peptide-Based Pan-Influenza A Vaccine: A Double Blind, Randomised Clinical Trial of Immunogenicity and Safety.” Vaccine 33 (2): 396–402. doi:10.1016/j.vaccine.2014.06.006.